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Data from recent trials have defined new standards of care for the treatment of stageIII–N2 non-small cell lung cancer (NSCLC).1–3 For selected patients in whom a
diagnosis of stage III–N2 disease was established preoperatively, chemoradiotherapy is
not inferior to chemoradiotherapy and surgery2 or to chemotherapy followed by surgery.3
In view of its lower morbidity and mortality, chemoradiotherapy can be considered the
standard treatment in patients presenting with stage III–N2 disease, even though locore-
gional control is suboptimal in nonsurgical treatment arms. Recent improvements in
preoperative staging techniques, including the availability of multislice CT scans, positron
emission tomography with 18-fluorodeoxyglucose (FDG-PET), and endoscopic tech-
niques, have called into question the relevance of the present staging system, which was
derived from analysis of a selected North American population.4 This analysis of the
current nodal descriptors for NSCLC by the staging committee of the International
Association for the Study of Lung Cancer (IASLC) at least partially answers these
questions.5
The IASLC group developed and analyzed a truly international database consisting
of 100,869 lung cancer cases managed within the time frame of 1990 to 2000. Of these,
38,264 cases with no evidence of metastatic disease after “clinical” N staging (which
included a mediastinoscopy) and 28,371 surgically managed patients provided informa-
tion on “pathologic” N staging. This analysis confirms the validity of the current nodal
staging system in determining prognosis of patients with N2 or N3 disease. A major new
finding is the identification of three distinct prognostic groups in patients undergoing
resection without any induction therapy—namely, single-zone N1 disease, multiple-zone
N1 or single N2 disease, and multiple-zone N2 disease. Observed differences in survival
between surgical and nonsurgical stages in the analysis highlight, once again, the
limitations of available noninvasive staging techniques.
A major drawback of the present analysis is the absence of data relating to
FDG-PET staging, a process that can exclude up to 30% of patients who are referred for
radical radiotherapy.6 The resulting stage migration from exclusion of patients with distant
metastases in this fashion will lead to a better survival in patients with stage III–N2
disease who are treated with chemoradiotherapy. Another limitation is the lack of data on
the size of nodal masses, a factor that influences the likelihood of achieving a pathological
complete remission with chemoradiotherapy. In the recent intergroup (INT) 0139 trial,
pathological complete remissions were observed in 46% of mediastinal nodes treated
using a preoperative induction chemoradiotherapy scheme to 45 Gy.2 Comparable data
after high-dose chemoradiotherapy are limited for patients with NSCLC, but data from
patients with head and neck cancers have revealed that post chemoradiotherapy nodal
control rates were 91% at 2 years when nodal volumes were 3 cm3; this decreased to
64% for nodal masses 3.0 cm3 (p  0.021).7
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For radiation oncologists, the findings of the IASLC
analysis indicate that optimal staging of mediastinal disease is
required not only for target volume definition; it also provides
important prognostic information on outcomes of local treat-
ments such as concurrent chemoradiotherapy. The staging of
nodal disease has increased in importance as elective medi-
astinal nodal irradiation has increasingly been replaced by
involved-field radiotherapy (IFRT), largely because of the
findings from nonrandomized trials that revealed a low inci-
dence of isolated “out-of-field” nodal failures.8 A randomized
clinical trial comparing elective mediastinal nodal irradiation
(to a dose of 60–64 Gy) with IFRT (to a dose of 68–74 Gy)
in stage III NSCLC has been presented in abstract form.9 In
the IFRT arm, comparable local tumor control (41 versus
49%), reduced incidence of radiation pneumonitis (29% ver-
sus 17%, p  0.044), and a superior 3-year survival were
observed. Only 7% of patients treated with IFRT developed
failures in elective nodal regions; this finding supports the use
of IFRT as the standard approach by the European Organi-
zation for Research and Treatment of Cancer.10
Many studies have defined IFRT fields by including
nodes with a short-axis diameter of 1 cm. FDG-PET is
superior to CT scans alone for staging the mediastinum,11 and
early experience has been reported of IFRT being defined
using only positron emission tomography (PET)-positive
nodal stations.12 Nevertheless, a meta-analysis has reported
that FDG-PET–negative nodes measuring 16 mm in
NSCLC had a posttest probability of metastatic disease of
21%.13 This suggests that pathological confirmation of nodal
status is justified when inclusion of enlarged, PET-negative
nodes will lead to much larger, potentially toxic treatment
fields. Ideally, IFRT planning should use the endoscopic
techniques that are used increasingly for preoperative stag-
ing.14–15 For example, a prospective study comparing endobron-
chial ultrasound-guided transbronchial needle aspiration with
PET and CT scans revealed an accuracy of 98% and a sensitivity
and specificity of 92 and 100%, respectively, for endobronchial
ultrasound-guided transbronchial needle aspiration.15 No com-
plications were reported in 103 evaluated patients in whom the
procedure was performed under conscious sedation15; this find-
ing supports a greater use of endoscopic procedures to stage
patients before thoracic chemoradiotherapy.
Once metastatic nodal disease has been identified, the
next step in planning IFRT is the addition of margins for both
microscopic disease and nodal motion. Up to 63% of patients
with nodal metastases in NSCLC will also show evidence of
microscopic extranodal tumor extension.16 Another study has
reported nodal extracapsular extension in 42% of patients,
which correlated with a larger node size; the authors recom-
mend a margin of 3 mm around the nodes for microscopic
disease when pathologic lymph nodes are 20 mm, and
margins of 8 mm for nodes 30 mm.17 Intrafraction nodal
motion, characterized using four-dimensional CT scans, was
maximal in the craniocaudal axis (mean 4.7  2.3 mm), with
corresponding mediolateral and ventrodorsal mobility of
2.8  1.9 and 2.4  1.8 mm, respectively.18 The mean
three-dimensional displacement of nodal mass was 6.2  2.9
mm, but it exceeded 10 mm in 5 of the 47 nodes studied. Both
these findings suggest that an approach of contouring nodal
regions19 may be more appropriate when four-dimensional
CT-based planning is unavailable.
The presence metastases in multiple nodal stations will
lead to larger radiation fields; this has been shown to increase
the risk of radiation-induced esophagitis.20 Moreover, metas-
tases in multiple nodal stations also identify patients in whom
the risk of distant metastases is high. To optimize the local
component in treatment of stage III–N2 NSCLC, more pro-
spective data on nodal parameters, including tumor bulk and
FDG-PET response to any prior treatment, should be col-
lected in future trials. A clear focus for the future should be
the optimal integration of new molecular targeted agents with
both IFRT and concurrent chemoradiotherapy, to improve
the therapeutic index for high-risk patients with stage III
NSCLC.
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